PMID- 18777587
OWN - NLM
STAT- MEDLINE
DCOM- 20081218
LR  - 20211020
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 14
IP  - 33
DP  - 2008 Sep 7
TI  - New serological biomarkers of inflammatory bowel disease.
PG  - 5115-24
AB  - Serological biomarkers in inflammatory bowel disease (IBD) are a rapidly 
      expanding list of non-invasive tests for objective assessments of disease 
      activity, early diagnosis, prognosis evaluation and surveillance. This review 
      summarizes both old and new biomarkers in IBD, but focuses on the development and 
      characterization of new serological biomarkers (identified since 2007). These 
      include five new anti-glycan antibodies, anti-chitobioside IgA (ACCA), 
      anti-laminaribioside IgG (ALCA), anti-manobioside IgG (AMCA), and antibodies 
      against chemically synthesized (Sigma) two major oligomannose epitopes, Man 
      alpha-1,3 Man alpha-1,2 Man (SigmaMan3) and Man alpha-1,3 Man alpha-1,2 Man 
      alpha-1,2 Man (SigmaMan4). These new biomarkers serve as valuable complementary 
      tools to existing biomarkers not only in differentiating Crohn's disease (CD), 
      ulcerative colitis (UC), normal and other non-IBD gut diseases, but also in 
      predicting disease involvement (ileum vs colon), IBD risk (as subclinical 
      biomarkers), and disease course (risk of complication and surgery). 
      Interestingly, the prevalence of the antiglycan antibodies, including 
      anti-Saccharomyces cerevisiae antibodies (ASCA), ALCA and AMCA, was found to be 
      associated with single nucleotide polymorphisms (SNPs) of IBD susceptible genes 
      such as NOD2/CARD15, NOD1/CARD4, toll-like receptors (TLR) 2 and 4, and 
      beta-defensin-1. Furthermore, a gene dosage effect was observed: anti-glycan 
      positivity became more frequent as the number of NOD2/CARD15 SNPS increased. 
      Other new serum/plasma IBD biomarkers reviewed include ubiquitination factor E4A 
      (UBE4A), CXCL16 (a chemokine), resistin, and apolipoprotein A-IV. This review 
      also discusses the most recent studies in IBD biomarker discovery by the 
      application of new technologies such as proteomics, fourier transform 
      near-infrared spectroscopy, and multiplex enzyme-linked immunosorbent assay 
      (ELISA)'s (with an emphasis on cytokine/chemokine profiling). Finally, the 
      prospects of developing more clinically useful novel diagnostic algorithms by 
      incorporating new technologies in serological biomarker profiling and integrating 
      multiple biomarkers with bioinformatics analysis/modeling are also discussed.
FAU - Li, Xuhang
AU  - Li X
AD  - Division of Gastroenterology, Department of Medicine, Johns Hopkins University 
      School of Medicine, 720 Rutland Ave, 918 Ross Research Bldg, Baltimore, MD 21205, 
      United States. xuhang@jhmi.edu
FAU - Conklin, Laurie
AU  - Conklin L
FAU - Alex, Philip
AU  - Alex P
LA  - eng
GR  - K01 DK062264/DK/NIDDK NIH HHS/United States
GR  - R21 DK077064/DK/NIDDK NIH HHS/United States
GR  - 5R21DK77064/DK/NIDDK NIH HHS/United States
GR  - K01-DK62264/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Biomarkers)
RN  - 0 (Polysaccharides)
SB  - IM
MH  - Antibodies, Anti-Idiotypic/*blood
MH  - Biomarkers/blood
MH  - Humans
MH  - Inflammatory Bowel Diseases/*blood/diagnosis
MH  - Polysaccharides/*immunology
MH  - Prognosis
PMC - PMC2744000
EDAT- 2008/09/09 09:00
MHDA- 2008/12/19 09:00
PMCR- 2008/09/07
CRDT- 2008/09/09 09:00
PHST- 2008/09/09 09:00 [pubmed]
PHST- 2008/12/19 09:00 [medline]
PHST- 2008/09/09 09:00 [entrez]
PHST- 2008/09/07 00:00 [pmc-release]
AID - 10.3748/wjg.14.5115 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2008 Sep 7;14(33):5115-24. doi: 10.3748/wjg.14.5115.